Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 0.00% | |
Golden Cross | Bullish | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
BB Squeeze Ended | Range Expansion | 0.00% | |
180 Bullish Setup | Bullish Swing Setup | 7.93% | |
Pocket Pivot | Bullish Swing Setup | 7.93% | |
Bollinger Band Squeeze | Range Contraction | 7.93% | |
NR7 | Range Contraction | 7.93% | |
NR7-2 | Range Contraction | 7.93% | |
Bollinger Band Squeeze | Range Contraction | 9.17% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 10 hours ago |
Up 5% | about 10 hours ago |
Up 1 ATR | about 10 hours ago |
Rose Above 20 DMA | about 11 hours ago |
Bullish 180 Entry | about 11 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 08/01/2024
BioCryst Pharmaceuticals, Inc. Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Disease Chemical Compounds Influenza Coronavirus Enzymes Viruses Medicinal Chemistry Angioedema Hereditary Angioedema Drug Design Kallikrein Seasonal Influenza Crystallography Acetamides Gout Protease Inhibitor
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 7.95 |
52 Week Low | 4.03 |
Average Volume | 3,909,843 |
200-Day Moving Average | 5.75 |
50-Day Moving Average | 5.76 |
20-Day Moving Average | 6.35 |
10-Day Moving Average | 6.23 |
Average True Range | 0.33 |
RSI (14) | 60.32 |
ADX | 26.04 |
+DI | 31.08 |
-DI | 15.31 |
Chandelier Exit (Long, 3 ATRs) | 5.98 |
Chandelier Exit (Short, 3 ATRs) | 6.92 |
Upper Bollinger Bands | 6.83 |
Lower Bollinger Band | 5.88 |
Percent B (%b) | 0.83 |
BandWidth | 14.90 |
MACD Line | 0.09 |
MACD Signal Line | 0.12 |
MACD Histogram | -0.0266 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 7.51 | ||||
Resistance 3 (R3) | 7.44 | 7.08 | 7.37 | ||
Resistance 2 (R2) | 7.08 | 6.87 | 7.12 | 7.32 | |
Resistance 1 (R1) | 6.88 | 6.74 | 6.98 | 6.95 | 7.28 |
Pivot Point | 6.52 | 6.52 | 6.58 | 6.56 | 6.52 |
Support 1 (S1) | 6.32 | 6.31 | 6.42 | 6.39 | 6.06 |
Support 2 (S2) | 5.96 | 6.18 | 6.00 | 6.02 | |
Support 3 (S3) | 5.76 | 5.96 | 5.97 | ||
Support 4 (S4) | 5.83 |